Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Chimerix participates in a conference call with Wedbush » 08:25
07/12/21
07/12
08:25
07/12/21
08:25
CMRX

Chimerix

$7.77 /

+0.14 (+1.83%)

Analyst Nierengarten…

Analyst Nierengarten holds a conference call with CEO Sherman and CFO Andriole on July 12 at 9 am hosted by Wedbush.

ShowHide Related Items >><<
CMRX Chimerix
$7.77 /

+0.14 (+1.83%)

CMRX Chimerix
$7.77 /

+0.14 (+1.83%)

06/07/21 H.C. Wainwright
Chimerix price target raised to $19 from $18 at H.C. Wainwright
05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
CMRX Chimerix
$7.77 /

+0.14 (+1.83%)

  • 21
    Jan
Conference/Events
Chimerix participates in a conference call with Wedbush » 04:55
07/12/21
07/12
04:55
07/12/21
04:55
CMRX

Chimerix

$7.77 /

+0.14 (+1.83%)

Analyst Nierengarten…

Analyst Nierengarten holds a conference call with CEO Sherman and CFO Andriole on July 12 at 9 am hosted by Wedbush.

ShowHide Related Items >><<
CMRX Chimerix
$7.77 /

+0.14 (+1.83%)

CMRX Chimerix
$7.77 /

+0.14 (+1.83%)

06/07/21 H.C. Wainwright
Chimerix price target raised to $19 from $18 at H.C. Wainwright
05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
CMRX Chimerix
$7.77 /

+0.14 (+1.83%)

  • 21
    Jan
Conference/Events
Chimerix participates in a conference call with Wedbush » 09:28
07/08/21
07/08
09:28
07/08/21
09:28
CMRX

Chimerix

$7.75 /

-0.12 (-1.52%)

Analyst Nierengarten…

Analyst Nierengarten holds a conference call with CEO Sherman and CFO Andriole on July 12 at 9 am hosted by Wedbush.

ShowHide Related Items >><<
CMRX Chimerix
$7.75 /

-0.12 (-1.52%)

CMRX Chimerix
$7.75 /

-0.12 (-1.52%)

06/07/21 H.C. Wainwright
Chimerix price target raised to $19 from $18 at H.C. Wainwright
05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
CMRX Chimerix
$7.75 /

-0.12 (-1.52%)

  • 21
    Jan
CMRX Chimerix
$7.75 /

-0.12 (-1.52%)

Over a month ago
Hot Stocks
Intercept appoints Berrey as President of Research & Development, CMO » 08:28
06/09/21
06/09
08:28
06/09/21
08:28
ICPT

Intercept

$19.80 /

+0.6 (+3.13%)

, CMRX

Chimerix

$8.43 /

+0.2 (+2.43%)

Intercept Pharmaceuticals…

Intercept Pharmaceuticals (ICPT) announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer, or CMO. Dr. Berrey was most recently President and Chief Executive Officer at Chimerix (CMRX).

ShowHide Related Items >><<
ICPT Intercept
$19.80 /

+0.6 (+3.13%)

CMRX Chimerix
$8.43 /

+0.2 (+2.43%)

ICPT Intercept
$19.80 /

+0.6 (+3.13%)

05/26/21 Piper Sandler
Piper bullish on Intercept into NASH data after FDA label revision
05/26/21 Jefferies
FDA guidelines for Intercept drug in-line with expectations, says Jefferies
05/26/21 B. Riley
B. Riley cuts Intercept to Neutral as case for NASH approval seen weakening
05/25/21 B. Riley
Intercept downgraded to Neutral from Buy at B. Riley
CMRX Chimerix
$8.43 /

+0.2 (+2.43%)

06/07/21 H.C. Wainwright
Chimerix price target raised to $19 from $18 at H.C. Wainwright
05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
ICPT Intercept
$19.80 /

+0.6 (+3.13%)

CMRX Chimerix
$8.43 /

+0.2 (+2.43%)

  • 21
    Jan
  • 18
    Aug
ICPT Intercept
$19.80 /

+0.6 (+3.13%)

CMRX Chimerix
$8.43 /

+0.2 (+2.43%)

Recommendations
Chimerix price target raised to $19 from $18 at H.C. Wainwright » 06:06
06/07/21
06/07
06:06
06/07/21
06:06
CMRX

Chimerix

$8.69 /

+0.3 (+3.58%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White raised the firm's price target on Chimerix to $19 from $18 and keeps a Buy rating on the shares after the FDA approved Tembexa for smallpox.

ShowHide Related Items >><<
CMRX Chimerix
$8.69 /

+0.3 (+3.58%)

CMRX Chimerix
$8.69 /

+0.3 (+3.58%)

05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
04/23/21 Cowen
Chimerix assumed with Outperform from Market Perform at Cowen
CMRX Chimerix
$8.69 /

+0.3 (+3.58%)

  • 21
    Jan
CMRX Chimerix
$8.69 /

+0.3 (+3.58%)

Hot Stocks
Chimerix receives FDA approval for Tembexa for treatment of smallpox » 14:11
06/04/21
06/04
14:11
06/04/21
14:11
CMRX

Chimerix

$8.80 /

+0.41 (+4.89%)

Chimerix announced that…

Chimerix announced that the U.S. Food and Drug Administration has granted TEMBEXA tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients, including neonates. "We are delighted to report our first FDA approved products for the treatment of smallpox, particularly as the importance of pandemic preparedness has been put into focus over the last year. With this approval in hand, we now look forward to advancing our discussions with the Biomedical Advanced Research and Development Authority (BARDA) toward a procurement contract to support national preparedness," said Mike Sherman, Chief Executive Officer of Chimerix.

ShowHide Related Items >><<
CMRX Chimerix
$8.80 /

+0.41 (+4.89%)

CMRX Chimerix
$8.80 /

+0.41 (+4.89%)

05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
04/23/21 Cowen
Chimerix assumed with Outperform from Market Perform at Cowen
CMRX Chimerix
$8.80 /

+0.41 (+4.89%)

  • 21
    Jan
CMRX Chimerix
$8.80 /

+0.41 (+4.89%)

Hot Stocks
FDA approves Chimerix drug to treat smallpox » 13:41
06/04/21
06/04
13:41
06/04/21
13:41
CMRX

Chimerix

$8.75 /

+0.36 (+4.29%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration announced it has approved Tembexa to treat smallpox. "Although the World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980, there have been longstanding concerns that the virus that causes smallpox, the variola virus, could be used as a bioweapon... Although naturally occurring smallpox no longer exists, concerns about potential uses of variola virus as a bioweapon has made smallpox drug development an important component of the U.S. medical countermeasures response. Because smallpox is eradicated, the effectiveness of Tembexa was studied in animals infected with viruses that are closely related to the variola virus. Effectiveness was determined by measuring animals' survival at the end of the studies. More animals treated with Tembexa survived compared to the animals treated with placebo. FDA approved Tembexa under the agency's Animal Rule, which allows findings from adequate and well-controlled animal efficacy studies to serve as the basis of an approval when it is not feasible or ethical to conduct efficacy trials in humans," the FDA stated. FDA granted approval of Tembexa to Chimerix. Reference Link

ShowHide Related Items >><<
CMRX Chimerix
$8.75 /

+0.36 (+4.29%)

CMRX Chimerix
$8.75 /

+0.36 (+4.29%)

05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
04/23/21 Cowen
Chimerix assumed with Outperform from Market Perform at Cowen
CMRX Chimerix
$8.75 /

+0.36 (+4.29%)

  • 21
    Jan
CMRX Chimerix
$8.75 /

+0.36 (+4.29%)

Earnings
Werewolf Therapeutics appoints Mike Sherman to board of directors » 07:03
05/28/21
05/28
07:03
05/28/21
07:03
HOWL

Werewolf Therapeutics

$14.85 /

+1.92 (+14.85%)

, CMRX

Chimerix

$7.93 /

-0.4 (-4.80%)

Werewolf Therapeutics…

Werewolf Therapeutics (HOWL) announced the appointment of Mike Sherman, CEO of Chimerix (CMRX), as a member of its board of directors.

ShowHide Related Items >><<
HOWL Werewolf Therapeutics
$14.85 /

+1.92 (+14.85%)

CMRX Chimerix
$7.93 /

-0.4 (-4.80%)

HOWL Werewolf Therapeutics
$14.85 /

+1.92 (+14.85%)

05/25/21
Fly Intel: Top five analyst initiations
05/25/21 SVB Leerink
SVB Leerink bullish on Werewolf Therapeutics, initiates with an Outperform
05/25/21 SVB Leerink
Werewolf Therapeutics initiated with an Outperform at SVB Leerink
05/25/21 Evercore ISI
Werewolf Therapeutics initiated with an Outperform at Evercore ISI
CMRX Chimerix
$7.93 /

-0.4 (-4.80%)

05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
04/23/21 Cowen
Chimerix assumed with Outperform from Market Perform at Cowen
CMRX Chimerix
$7.93 /

-0.4 (-4.80%)

  • 30
    Apr
  • 21
    Jan
HOWL Werewolf Therapeutics
$14.85 /

+1.92 (+14.85%)

CMRX Chimerix
$7.93 /

-0.4 (-4.80%)

Conference/Events
Cowen to hold a virtual summit » 04:55
05/21/21
05/21
04:55
05/21/21
04:55
CMRX

Chimerix

$7.90 /

+ (+0.00%)

, MGTA

Magenta Therapeutics

$11.17 /

+0.265 (+2.43%)

, RLAY

Relay Therapeutics

$30.79 /

+0.71 (+2.36%)

, SNDX

Syndax

$17.83 /

+0.08 (+0.45%)

, ATRA

Atara Biotherapeutics

$14.32 /

+0.27 (+1.92%)

, KURA

Kura Oncology

$23.49 /

-0.48 (-2.00%)

, XFOR

X4 Pharmaceuticals

$7.48 /

+0.11 (+1.49%)

, STRO

Sutro Biopharma

$18.40 /

-1.885 (-9.29%)

2nd Annual Virtual…

2nd Annual Virtual Oncology Innovation Summit: Insights for ASCO & EHA will be held on May 20-21.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$7.48 /

+0.11 (+1.49%)

STRO Sutro Biopharma
$18.40 /

-1.885 (-9.29%)

SNDX Syndax
$17.83 /

+0.08 (+0.45%)

RLAY Relay Therapeutics
$30.79 /

+0.71 (+2.36%)

MGTA Magenta Therapeutics
$11.17 /

+0.265 (+2.43%)

KURA Kura Oncology
$23.49 /

-0.48 (-2.00%)

CMRX Chimerix
$7.90 /

+ (+0.00%)

ATRA Atara Biotherapeutics
$14.32 /

+0.27 (+1.92%)

CMRX Chimerix
$7.90 /

+ (+0.00%)

05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
04/23/21 Cowen
Chimerix assumed with Outperform from Market Perform at Cowen
MGTA Magenta Therapeutics
$11.17 /

+0.265 (+2.43%)

05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
01/07/21
Fly Intel: Top five analyst initiations
RLAY Relay Therapeutics
$30.79 /

+0.71 (+2.36%)

03/29/21 JMP Securities
Relay Therapeutics price target lowered to $50 from $66 at JMP Securities
01/29/21 JPMorgan
Relay Therapeutics price target raised to $52 from $36 at JPMorgan
12/15/20 H.C. Wainwright
Relay Therapeutics price target raised to $57 from $54 at H.C. Wainwright
12/08/20 JMP Securities
Relay Therapeutics initiated with an Outperform at JMP Securities
SNDX Syndax
$17.83 /

+0.08 (+0.45%)

04/21/21 Baird
Syndax price target lowered to $30 from $39 at Baird
02/24/21 Piper Sandler
Kura Oncology price target lowered to $30 from $34 at Piper Sandler
02/18/21 B. Riley
Syndax initiated with Buy, $30 price target at B. Riley
02/17/21 B. Riley
Syndax initiated with a Buy at B. Riley Securities
ATRA Atara Biotherapeutics
$14.32 /

+0.27 (+1.92%)

05/13/21
Fly Intel: Top five analyst upgrades
05/13/21 JPMorgan
Atara Biotherapeutics upgraded to Overweight from Neutral at JPMorgan
03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
KURA Kura Oncology
$23.49 /

-0.48 (-2.00%)

05/04/21 Credit Suisse
Kura Oncology assumed with an Outperform at Credit Suisse
04/26/21 Credit Suisse
Kura Oncology assumed with an Outperform at Credit Suisse
02/24/21 H.C. Wainwright
H.C. Wainwright trims Kura Oncology price target to $43 after Q4 report
XFOR X4 Pharmaceuticals
$7.48 /

+0.11 (+1.49%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
STRO Sutro Biopharma
$18.40 /

-1.885 (-9.29%)

05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
XFOR X4 Pharmaceuticals
$7.48 /

+0.11 (+1.49%)

STRO Sutro Biopharma
$18.40 /

-1.885 (-9.29%)

SNDX Syndax
$17.83 /

+0.08 (+0.45%)

RLAY Relay Therapeutics
$30.79 /

+0.71 (+2.36%)

MGTA Magenta Therapeutics
$11.17 /

+0.265 (+2.43%)

KURA Kura Oncology
$23.49 /

-0.48 (-2.00%)

CMRX Chimerix
$7.90 /

+ (+0.00%)

ATRA Atara Biotherapeutics
$14.32 /

+0.27 (+1.92%)

  • 21
    Jan
  • 09
    Dec
  • 09
    Dec
  • 09
    Dec
  • 09
    Dec
  • 16
    Jul
  • 25
    Jun
  • 27
    May
STRO Sutro Biopharma
$18.40 /

-1.885 (-9.29%)

SNDX Syndax
$17.83 /

+0.08 (+0.45%)

CMRX Chimerix
$7.90 /

+ (+0.00%)

ATRA Atara Biotherapeutics
$14.32 /

+0.27 (+1.92%)

XFOR X4 Pharmaceuticals
$7.48 /

+0.11 (+1.49%)

RLAY Relay Therapeutics
$30.79 /

+0.71 (+2.36%)

Conference/Events
Cowen to hold a virtual summit » 10:46
05/20/21
05/20
10:46
05/20/21
10:46
CMRX

Chimerix

$7.91 /

+0.01 (+0.13%)

, MGTA

Magenta Therapeutics

$11.15 /

+0.245 (+2.25%)

, RLAY

Relay Therapeutics

$30.86 /

+0.78 (+2.59%)

, SNDX

Syndax

$18.18 /

+0.43 (+2.42%)

, ATRA

Atara Biotherapeutics

$14.40 /

+0.35 (+2.49%)

, KURA

Kura Oncology

$23.97 /

+ (+0.00%)

, XFOR

X4 Pharmaceuticals

$7.54 /

+0.17 (+2.31%)

, STRO

Sutro Biopharma

$19.57 /

-0.71 (-3.50%)

2nd Annual Virtual…

2nd Annual Virtual Oncology Innovation Summit: Insights for ASCO & EHA will be held on May 20-21.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$7.54 /

+0.17 (+2.31%)

STRO Sutro Biopharma
$19.57 /

-0.71 (-3.50%)

SNDX Syndax
$18.18 /

+0.43 (+2.42%)

RLAY Relay Therapeutics
$30.86 /

+0.78 (+2.59%)

MGTA Magenta Therapeutics
$11.15 /

+0.245 (+2.25%)

KURA Kura Oncology
$23.97 /

+ (+0.00%)

CMRX Chimerix
$7.91 /

+0.01 (+0.13%)

ATRA Atara Biotherapeutics
$14.40 /

+0.35 (+2.49%)

CMRX Chimerix
$7.91 /

+0.01 (+0.13%)

05/06/21 H.C. Wainwright
Chimerix price target raised to $18 from $16 at H.C. Wainwright
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 Maxim
Chimerix initiated with a Buy at Maxim
04/23/21 Cowen
Chimerix assumed with Outperform from Market Perform at Cowen
MGTA Magenta Therapeutics
$11.15 /

+0.245 (+2.25%)

05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
01/07/21
Fly Intel: Top five analyst initiations
RLAY Relay Therapeutics
$30.86 /

+0.78 (+2.59%)

03/29/21 JMP Securities
Relay Therapeutics price target lowered to $50 from $66 at JMP Securities
01/29/21 JPMorgan
Relay Therapeutics price target raised to $52 from $36 at JPMorgan
12/15/20 H.C. Wainwright
Relay Therapeutics price target raised to $57 from $54 at H.C. Wainwright
12/08/20 JMP Securities
Relay Therapeutics initiated with an Outperform at JMP Securities
SNDX Syndax
$18.18 /

+0.43 (+2.42%)

04/21/21 Baird
Syndax price target lowered to $30 from $39 at Baird
02/24/21 Piper Sandler
Kura Oncology price target lowered to $30 from $34 at Piper Sandler
02/18/21 B. Riley
Syndax initiated with Buy, $30 price target at B. Riley
02/17/21 B. Riley
Syndax initiated with a Buy at B. Riley Securities
ATRA Atara Biotherapeutics
$14.40 /

+0.35 (+2.49%)

05/13/21
Fly Intel: Top five analyst upgrades
05/13/21 JPMorgan
Atara Biotherapeutics upgraded to Overweight from Neutral at JPMorgan
03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
KURA Kura Oncology
$23.97 /

+ (+0.00%)

05/04/21 Credit Suisse
Kura Oncology assumed with an Outperform at Credit Suisse
04/26/21 Credit Suisse
Kura Oncology assumed with an Outperform at Credit Suisse
02/24/21 H.C. Wainwright
H.C. Wainwright trims Kura Oncology price target to $43 after Q4 report
XFOR X4 Pharmaceuticals
$7.54 /

+0.17 (+2.31%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
STRO Sutro Biopharma
$19.57 /

-0.71 (-3.50%)

05/20/21 Piper Sandler
Sutro Biopharma ovarian cancer data 'impressive,' says Piper Sandler
01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
XFOR X4 Pharmaceuticals
$7.54 /

+0.17 (+2.31%)

STRO Sutro Biopharma
$19.57 /

-0.71 (-3.50%)

SNDX Syndax
$18.18 /

+0.43 (+2.42%)

RLAY Relay Therapeutics
$30.86 /

+0.78 (+2.59%)

MGTA Magenta Therapeutics
$11.15 /

+0.245 (+2.25%)

KURA Kura Oncology
$23.97 /

+ (+0.00%)

CMRX Chimerix
$7.91 /

+0.01 (+0.13%)

ATRA Atara Biotherapeutics
$14.40 /

+0.35 (+2.49%)

  • 21
    Jan
  • 09
    Dec
  • 09
    Dec
  • 09
    Dec
  • 09
    Dec
  • 16
    Jul
  • 25
    Jun
  • 27
    May
STRO Sutro Biopharma
$19.57 /

-0.71 (-3.50%)

SNDX Syndax
$18.18 /

+0.43 (+2.42%)

CMRX Chimerix
$7.91 /

+0.01 (+0.13%)

ATRA Atara Biotherapeutics
$14.40 /

+0.35 (+2.49%)

XFOR X4 Pharmaceuticals
$7.54 /

+0.17 (+2.31%)

RLAY Relay Therapeutics
$30.86 /

+0.78 (+2.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.